In vivo pharmaco-proteomic analysis of hydroxyurea induced changes in the sickle red blood cell membrane proteome.

Journal of Proteomics
Swati S GhatpandeSteven R Goodman

Abstract

Hydroxyurea (HU) is an effective drug for the treatment of sickle cell disease (SCD). The main clinical benefit of HU is thought to derive from its capacity to increase fetal hemoglobin (HbF) production. However, other effects leading to clinical benefit, such as improved blood rheology, have been suggested. In order to understand HU-induced changes at the proteomic level, we profiled sickle RBC membranes from of HU-treated and untreated patients. Our previous in vitro profiling studies on sickle RBC membranes identified a significant increase in predominantly anti-oxidant enzymes, protein repair and degradation components and a few RBC cytoskeletal proteins. In the present study, using 2D-DIGE (Two-Dimensional Difference In-Gel Electrophoresis) and tandem mass spectrometry, we detected 32 different proteins that significantly changed in abundance in the HU treatment group. The proteins that significantly increased in abundance were mostly membrane skeletal components involved in the regulation of RBC shape and flexibility, and those showing a significant decrease were components of the protein repair and degradation machinery. RBC palmitoylated membrane protein 55 (p55) is significantly increased in abundance at low (in vitro)...Continue Reading

References

Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·P RuffA Husain-Chishti
Jun 1, 1997·American Journal of Hematology·A ShartavaS R Goodman
Feb 7, 2003·Current Medicinal Chemistry·S Bruce King
Feb 14, 2004·Molecular & Cellular Proteomics : MCP·David G KakhniashviliSteven R Goodman
Nov 28, 2007·Experimental Biology and Medicine·Steven R GoodmanOvidiu Daescu
Nov 28, 2007·Experimental Biology and Medicine·Steven R GoodmanSudha Neelam
Oct 14, 2008·Experimental Biology and Medicine·Swati S GhatpandeSteven R Goodman
Jul 2, 2009·Journal of Proteomics·Giancarlo LiumbrunoLello Zolla

❮ Previous
Next ❯

Citations

Oct 17, 2013·Biochimica Et Biophysica Acta·Benjamin Barasa, Monique Slijper
Apr 8, 2011·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·N LionJ-D Tissot
Jan 20, 2011·Proteomics. Clinical Applications·Abhijit ChakrabartiSuchismita Halder
May 20, 2016·Proteomics. Clinical Applications·Raffaele Renella
Jul 17, 2013·Experimental Biology and Medicine·Steven R GoodmanMarko Zivanic
Aug 29, 2018·Journal of Clinical Pharmacology·Muhammad ZohaibShamshad Zarina
Dec 15, 2010·Expert Review of Proteomics·Susan YuditskayaGregory J Kato
Nov 18, 2011·Expert Review of Proteomics·Michel PrudentNiels Lion
Apr 22, 2011·Experimental Biology and Medicine·Sudha NeelamSteven R Goodman
Mar 3, 2021·Orphanet Journal of Rare Diseases·Nirmani YasaraSachith Mettananda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.